OCUL Ocular Therapeutix Inc.

4.48
+0.27  (+6%)
Previous Close 4.21
Open 4.24
Price To Book 24.89
Market Cap 211,439,075
Shares 47,196,222
Volume 374,853
Short Ratio
Av. Daily Volume 924,822

NewsSee all news

  1. Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT
  2. Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares
  3. Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
  4. Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
  5. Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval June 21, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 data May 20, 2019 did not meet primary endpoint.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 initial data released April and May 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT
  2. Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares
  3. Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
  4. Ocular Therapeutix™ Reports Second Quarter 2019 Financial Results and Business Update
  5. Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
  6. Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
  7. Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
  8. Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  9. Ocular Therapeutix™ Announces Christopher White as Senior Vice President, Head of Business and Corporate Development
  10. Ocular Therapeutix™ Announces Patricia Kitchen as Chief Operations Officer
  11. Implied Volatility Surging for Ocular (OCUL) Stock Options
  12. Ocular Therapeutix™ Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States
  13. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  14. Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More
  15. FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule
  16. Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  17. Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares
  18. Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price?
  19. Options Traders Expect Huge Moves in Ocular (OCUL) Stock
  20. Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences